CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma

Trial Details

NCT ID

NCT06834529

Phase

PHASE1 / PHASE2

Sponsor

Affiliated Hospital to Academy of Military Medical Sciences

Status

RECRUITING

Cancer Type

Leukemia

Interventions

• CAR2219-T cells

Locations (sample)

• Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

• Signed written informed consent;
• Relapsed/refractory CD19/CD22 positive B cell Leukemia or Lymphoma must be assured and meet one of the following conditions: (1) Confirmation for e…
• All genders, ages: 14 to 75 years
• Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.